Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease Research Program with NP-251

Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share an update on the Company’s drug NP-251, or Repirinast, which is being investigated in the treatment of Chronic Kidney Disease (CKD).

Mr. Moreau explains to Proactive that the pre-clinical animal model of kidney fibrosis showed Repirinast reduced fibrosis by 50% with statistical significance.

As part of the new CKD research program, Algernon Pharmaceuticals will also investigate the use of Repirinast in acute interstitial nephritis, which causes inflammation of parts of the kidney.